Doxorubicin liposomal - Jina Pharmaceuticals

Drug Profile

Doxorubicin liposomal - Jina Pharmaceuticals

Latest Information Update: 21 Oct 2015

Price : $50

At a glance

  • Originator Jina Pharmaceuticals
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Sep 2015 Registered for Cancer in India (IV) before September 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top